by Elena Iemma | May 17, 2021 | News
PROVIDENCE, RI, May 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation” in NPJ Vaccines. This research identifies...
by Elena Iemma | Feb 17, 2021 | News
PROVIDENCE, RI, February 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today announces its participation in the INDIGO consortium – a partnership of public and private research and development organizations from the EU, India, and United States (funded by the...
by Elena Iemma | Feb 17, 2021 | Events, Webinars
EpiVax CEO/CSO Annie De Groot hosted a talk for the FDA Office of Tissues and Advanced Therapies (OTAT) group on February 11, 2021. Annie presented the latest on EpiVax’s iVAX Toolkit in her talk “Epitope Selection for Cancer Vaccines”. JanusMatrix,...
by Adam | Mar 24, 2020 | News
March 24, 2020 Niel, Belgium: eTheRNA Immunotherapies nv (‘eTheRNA’ or ‘The Company’), a clinical-stage company developing vaccines and immunotherapies from its proprietary mRNA TriMix platform, today announced that a consortium has been formed with North American and...
by Adam | Mar 20, 2020 | News
Providence biotech company working to create coronavirus vaccine by TAMARA SACHARCZYK, NBC 10 NEWS Wednesday, March 18th 2020 Find the full story here EpiVax in Providence. (WJAR) A team of local scientists are on the front lines of a global pandemic as they race...